Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Drugs - Real World Outcomes|May 9, 2026
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerDianne Bosch, Kim J M van der Velden, Aart Beeker, et al.
Nature Medicine|February 2, 2023
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trialJeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot StudyBastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
European Urology Oncology|October 12, 2019
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer RegistryMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|August 24, 2019
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the NetherlandsHans M Westgeest, Malou C P Kuppen, Alphonsus J M van den Eertwegh, et al.
Journal of Palliative Medicine|August 20, 2021
High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-RegistryHans M Westgeest, Malou C P Kuppen, Fons A J M van den Eertwegh, et al.
JAMA Network Open|October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSabine Schmid, Aurelius Omlin, Celestia Higano, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Drugs - Real World Outcomes|May 9, 2026
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerDianne Bosch, Kim J M van der Velden, Aart Beeker, et al.
Nature Medicine|February 2, 2023
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trialJeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot StudyBastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
European Urology Oncology|October 12, 2019
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer RegistryMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|August 24, 2019
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the NetherlandsHans M Westgeest, Malou C P Kuppen, Alphonsus J M van den Eertwegh, et al.
Journal of Palliative Medicine|August 20, 2021
High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-RegistryHans M Westgeest, Malou C P Kuppen, Fons A J M van den Eertwegh, et al.
JAMA Network Open|October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene AberrationsSabine Schmid, Aurelius Omlin, Celestia Higano, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Pageof 17